Case Report: Rare coexistence of primary Sjögren’s syndrome and IgA-type lymphoplasmacytic lymphoma successfully treated with rituximab and orelabrutinib
Background IgA-type lymphoplasmacytic lymphoma (LPL) is a rare type of non-Hodgkin lymphoma and is even rarer when combined with primary Sjögren’s syndrome (pSS). Currently, there is no unified early identification and standardized treatment plan. Methods and results This article reports a 67-year-old female patient with a history of pSS for more than 10 years. After she was admitted to the hospital with fever, multiple generalized lymph node enlargement and IgA-κ monoclonal immunoglobulinemia were found. After 18 months of treatment with glucocorticoids combined with traditional immunosuppressants (mycophenolate mofetil, cyclophosphamide, and iguratimod), lymph node enlargement persisted, and IgA levels fluctuated at a high level. Three consecutive bone marrow punctures and two lymph node biopsies revealed all benign lesions. A third lymph node resection biopsy and immunohistochemistry confirmed the diagnosis of IgA-type LPL. After six cycles of treatment with rituximab combined with orelabrutinib (RO regimen), the patient achieved complete remission. Subsequently, orelabrutinib monotherapy was continued as maintenance treatment. In October 2023, the patient remained stable, and orelabrutinib was discontinued. After that, the patient was followed up at the outpatient clinic. As of July 2026, the patient was in good condition with no signs of recurrence. Conclusion This case suggests that lymphoma should be considered in patients with pSS who have monoclonal immunoglobulins, refractory elevated erythrocyte sedimentation rate, persistent lymph node enlargement, and high disease activity despite treatment with various immunosuppressants. Lymph node biopsy should be repeated if necessary. For patients with pSS and suspected or confirmed lymphoma, B-cell-targeted therapy should be considered as early as possible. Rituximab combined with orelabrutinib was effective in this patient with IgA-type LPL.
Authors
- Lei Zhang (ORCID: https://orcid.org/0000-0001-7242-5292)
- 高招猛
- Pengbo Xiao
Institutions
- Shengli Oilfield Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.2015223
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00